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which increases sIL-6R plasma levels, thereby enhancing theRole of different dialysis membranes in the release of interleu-
inflammatory effects of IL-6.kin-6-soluble receptor in uremic patients.
Background. Interleukin-6 (IL-6) exerts its actions through
a cell-surface receptor system that consists of two transmem-
brane subunits: the IL-6 binding glycoprotein gp 80 (IL-6R)
Life expectancy is greatly reduced in patients undergo-and the signal-transducing component (gp 130). Soluble forms
ing dialysis therapy [1]. The causes of the high rate ofof the IL-6R (sIL-6R) are generated by shedding of the mem-
brane-associated proteins. The sIL-6R binds the ligand IL-6 mortality and morbidity (mainly cardiovascular and in-
with comparable affinity as the membrane-associated IL-6R fection) remain unclear and the object of study [2, 3].
and enhances the actions of IL-6. Some dialysis-related alterations in the immune and
Methods. Our aim was to evaluate the role of both uremia
host-defense systems may play a relevant role in thisand different dialysis membranes on peripheral blood mononu-
crucial issue, and seem to correlate to the high peripheralclear cell (PBMC) release (either in absence or in presence of
mitogen stimulation) and plasma levels of sIL-6R. Ten patients blood mononuclear cell (PBMC) production of proin-
chronically dialyzed with cuprophan membranes (CU), eight flammatory cytokines, such as interleukin-1 (IL-1), tu-
patients on regular dialysis treatment with polymethylmetha- mor necrosis factor (TNF), and IL-6 [4–6]. Other condi-crylate (PMMA) membranes, 11 uremic nondialyzed patients
tions resulting from an up-regulated proinflammatory(UR), and 12 healthy subjects (CON) were included in the
cytokine production and release may include dialysis amy-study.
Results. PBMCs harvested from CU spontaneously released loidosis [7], malnutrition [8, 9], and atherosclerosis [10].
significantly (P , 0.01) greater amounts of sIL-6R (881.8 6 An enhanced spontaneous production of IL-6 by
80.1 pg/mL), as compared with CON (267.5 6 26.5 pg/mL),
PBMCs harvested from dialyzed patients treated withUR (258.4 6 38.1 pg/mL), and PMMA (288.4 6 24.6 pg/mL).
cuprophan membranes, as compared with healthy con-Under mitogenic stimulation, the sIL-6R release was signifi-
cantly (P , 0.01) increased in all groups. The greater PBMC trols and uremic nondialyzed patients, was demonstrated
production of sIL-6R in CU was followed by significantly (P , by our group [11, 12].
0.01) higher levels of circulating soluble receptors (48.7 6 2.5 Interleukin-6 exerts its actions through a cell surfaceng/mL, 60%), as compared with CON (30.5 6 1.9 ng/mL). UR
receptor system that consists of two transmembrane sub-also showed high circulating levels of sIL-6R (53.3 6 5.9
units: the IL-6 binding gp 80 (named IL-6R) and theng/mL), probably secondary to an impaired urinary excretion.
Circulating levels of sIL-6R in PMMA were comparable to signal-transducing component gp 130, which is not ligand
CON (30.3 6 3.3 ng/mL). Either the absence of monocyte binding [13, 14]. IL-6 first binds to the IL-6R, and this
activation or the adsorption of sIL-6R on the hydrophobic
complex subsequently associates with two gp 130 mole-PMMA surface could explain this finding.
cules. The IL-6 binds IL-6R with low affinity (Kd 5Conclusions. These results suggest an important role for
poor dialysis biocompatibility of CU on the release of sIL-6R, 1029 mol/L), but the IL-6/IL-6R complex may trigger its
association with gp 130 (two molecules), forming a high-
affinity, IL-6–binding site (Kd 5 10211 mol/L). Therefore,Key words: biocompatibility, hemodialysis, cytokine, cuprophan mem-
the signal transducing complex of the IL-6 receptor sys-branes, polymethylmethacrylate membranes, peripheral blood mono-
nuclear cells, inflammation. tem on cell membrane consists of a disulfide-linked di-
mer of gp 130 associated with an IL-6/IL-6R complexReceived for publication October 6, 1999
[15, 16].and in revised form January 25, 2000
Accepted for publication February 7, 2000 Soluble forms of IL-6R and gp 130, detected in various
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generated mainly by the shedding of membrane-associ- Neither group of patients on RDT changed their mem-
ated proteins [15]. In particular, the 80 kD membrane- brane (cuprophan or PMMA, respectively) for one year
bound IL-6R is proteolytically cleaved with release of a before the study. No difference was evidenced in their
55 kD soluble protein (named sIL-6R). The sIL-6R residual renal function (2.2 6 0.6 SD and 1.9 6 0.4
(55 kD) binds the ligand IL-6 with comparable affinity mL/min in CU and PMMA, respectively).
as the membrane-associated receptor (IL-6R 80 kD). No patient had diabetes mellitus or any clinical or
Unlike all known soluble cytokine receptors, sIL-6R has laboratory evidence for infectious, neoplastic, or in-
no antagonistic role but, in contrast, can act as an agonist flammatory disease. No patient was consuming any drug
of IL-6 activity and may promote or enhance the re- that interfered with the immune response. No difference
sponse to IL-6 in some biological assay [15, 16]. was evidenced in the percent of smokers or in alcohol
While plasma levels and PBMC release of circulating intake. All subjects gave their informed consent prior to
receptors of other cytokines have been extensively stud- the study.
ied [18–20], no data are available about sIL-6R PBMC In dialyzed patients (either on cuprophan or PMMA
release and its plasma concentrations in uremic patients. membrane), dialysate was filtered through hydrophobic
The aim of this study was therefore to investigate the membranes and prepared with bicarbonate dry powder
sIL-6R kinetics in both dialyzed and nondialyzed uremic cartridges; Kt/V urea, estimated according to the Daugir-
patients. In particular, we evaluated and compared with das equation [21], was kept between 1.2 and 1.3, and the
normal healthy subjects (control group) the sIL-6R circu- protein catabolic rate was kept between 1.0 and 1.3
lating levels in uremic nondialyzed patients or in patients g/kg/day.
regularly dialyzed with two membranes of different bio-
compatibility toward the leukocyte and the complement Blood samples and cell cultures
system. To better understand the mechanisms determin- In all groups, heparinized blood samples of 15 mL
ing plasma levels of sIL-6R, we also evaluated the sIL-6R were collected in the morning for obtaining plasma sam-
production (basal and stimulated) by PBMCs harvested ples and PBMCs. In dialyzed patients, blood samples
from the same groups of subjects and sIL-6R urinary were drawn just before the onset of the second dialysis
excretion in both controls and uremic nondialyzed pa- session of the week. Although a day-to-day variability
tients. Finally, to ascertain the role of IL-6 on influencing in cytokine release by PBMCs has been reported by
sIL-6R plasma levels and PBMC release, the concentra- Pereira et al [18], preliminary observations by our group,
tion of this cytokine on the same plasma and PBMC with repeated blood samples randomly drawn before the
supernatant samples was also measured.
three different dialysis treatments of the week and during
interdialytic periods, did not show significant differences
METHODS in cytokine production by lymphomononuclear cells.
These results are in agreement with those recently ob-Patient selection
tained by Balakrishnan et al [20].Four groups of subjects were enrolled in this study:
Peripheral blood mononuclear cells were harvested(1) 10 patients (6 males and 4 females, mean age, 52 6
and established in cultures as previously described12.4 SD years) on regular dialysis treatment (RDT) con-
[11, 12]. In brief, PBMCs were obtained by a Ficoll-sisting of dialysis three times a week for at least one year
Hypaque (Flow Laboratories, Irvine, UK) gradient den-prior to the study with new cuprophan membranes (CU;
sity centrifugation (400 3 g for 30 min). The mononu-mean membrane surface, 1.3 m2, thickness, 8 m; steriliza-
clear layer was then collected and washed twice withtion, ethylene oxide; filters manufactured by Bellco, Mir-
RPMI 1640 culture medium (Flow Laboratories), ul-andola, Italy); (2) 8 patients (5 males and 3 females;
trafiltered to avoid microbial product contaminationmean age, 48.6 6 8.4 SD years) on RDT for at least
(Gambro, Lund, Sweden). PBMCs were then resus-one year prior to the study, with a more biocompatible
pended in 15 mL polypropylene round-bottom tubessynthetic membrane [polymethylmethacrylate (PMMA);
(Falcon; Becton Dickinson, Lincoln Park, NJ, USA) atmodel B3.1.3A, mean membrane surface 1.3 m2, mem-
a concentration of 2 3 106/mL in an Iscove’s culturebrane thickness 20 m, sterilization: g-ray; filters manufac-
medium (Flow Laboratories) supplemented with 1%tured by Toray, Tokyo, Japan)]; (3) 11 patients (7 males
heat-inactivated fetal bovine serum (Sigma Chimica, Mi-and 4 females, mean age, 49.6 6 10.6 SD years) with
lan, Italy) and antibiotics (penicillin and streptomycin).advanced chronic renal failure (UR; mean glomerular
Peripheral blood mononuclear cell cultures were pre-filtration rate value, measured as the mean of creatinine
pared with and without a mitogenic stimulation with 10and urea clearance, 10.4 6 2.8 mL/min); and (4) 12
mg/mL of bacterial lipopolysaccharide (LPS; Sigma). Onhealthy laboratory staff volunteers (CON; 7 males and
the basis of previous studies from our lab and other5 females, mean age, 45.7 6 12.2 SD years) who served
as the control group. groups [12, 22, 23], this LPS dosage and the incubation
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time have been shown to induce the maximal stimulation
for the PBMC release of proinflammatory cytokines.
Peripheral blood mononuclear cells were cultured for
24 hours at 378C in a humidified atmosphere containing
5% CO2; cell-free supernatants were collected by centrif-
ugation and were stored at 2208C.
The cell cultures contained about 95% PBMCs with
a mean value of 76% lymphocytes (range 68 to 88%)
and 12% monocytes (range 8 to 16%); no difference was
observed in cell distribution (lymphocytes and mono-
cytes) in the four groups of subjects included in the study.
More than 98% PBMCs were viable, as determined by
trypan blue dye exclusion at the beginning of the culture, Fig. 1. Plasma circulating levels of soluble interleukin-6 receptor
and more than 90% were viable before supernatants (sIL-6R) in 8 healthy subjects (control), 11 uremic nondialyzed patients
(UR), 10 patients dialyzed with cuprophan membrane (CU), and 8were collected.
patients dialyzed with polymethylmethacrylate membranes (PMMA).
The results are expressed as mean 6 95% confidence intervals (obtainedUrine samples as 1.96 3 SEM). CU and UR show circulating levels of sIL-6R signifi-
cantly (P , 0.01) higher than in the other two groups.In healthy subjects and uremic nondialyzed patients,
urine was also collected for 12 hours after blood drawing.
Urine collections were accurately measured, and a urine
sample was stored at 2208C. dure was similar for the human IL-6 assay, and the lower
detection limit for this assay was ,0.70 pg/mL. The varia-Analytical determinations
tion coefficient of both interassay and intra-assay was ,5%.
Creatinine and urea concentrations were determined
on plasma and urine samples of control subjects and Statistical analysis
uremic nondialyzed patients with a Beckman autoana-
Statistical analysis was performed using the analysislyzer (Beckman Instruments, Fullerton, CA, USA).
of variance (ANOVA) followed by the Bonferroni test,
as post hoc test, and linear regression analysis. UnlessCytokine assays
otherwise reported, results are expressed as means 6Soluble IL-6 receptor and IL-6 concentrations in
SEM. The statistical significance was defined as P , 0.05.PBMC cultures supernatant, plasma, and urine samples
were evaluated by enzyme-linked immunosorbent assays
(ELISA) using two different commercially available kits RESULTS
(Quantikine; R&D Systems, Minneapolis, MN, USA, for Plasma levels of sIL-6R
both IL-6 and sIL-6R assays). All samples for a given
As shown in Figure 1, uremic patients dialyzed withassay (including standards and supernatant, plasma, and
cuprophan membranes (CU) and uremic nondialyzedurine samples) were analyzed in duplicate at the same
patients (UR) showed significantly (P , 0.01) highertime. In particular, the assay for human sIL-6R measures
plasma levels (expressed as means 6 95% confidencethe total amount of sIL-6R present in the samples (that
intervals) of sIL-6R (48.7 6 4.9 and 53.3 6 11.6 ng/mL,is, the total amount of free receptor plus the total amount
respectively) as compared with circulating values foundof receptor bound to IL-6) by employing a quantitative
in normal healthy controls (controls, 30.5 6 3.8 ng/mL)sandwich enzyme immunoassay technique. In brief, a
and uremic patients dialyzed with PMMA membranesmonoclonal antibody specific for sIL-6R was precoated
(PMMA, 30.3 6 6.4 ng/mL). No difference was observedonto a microtiter plate. Standards and samples were pi-
in sIL-6R plasma levels between CU and UR and be-petted into the wells; thus, any sIL-6R present was bound
tween controls and PMMA. In Figure 1, it is also evidentby the immobilized antibody. After washing away any
that no overlap was present for data obtained from CUunbound substance, an enzyme-linked polyclonal anti-
and UR versus controls and PMMA.body specific for sIL-6R was added to the wells. After
washing, a substrate solution was added to the wells, and
sIL-6R production by unstimulated andcolor developed in proportion to the amount of sIL-6R
stimulated PBMCsbound in the initial step. The color development was
As reported in Figure 2, uremic patients dialyzed withstopped after 30 minutes, and the intensity of the color
cuprophan membranes (CU) showed a significantly (P ,was measured at 450 nm. The lower detection limit of
0.01) higher value of sIL-6R release by unstimulatedthis assay was ,3.5 pg/mL, and the variation coefficient
of both interassay and intra-assay was ,10%. This proce- PBMC (881.8 6 80.1 pg/mL) as compared with sIL-6R
Memoli et al: IL-6–soluble receptor in uremia420
Fig. 2. Soluble IL-6 receptor (sIL-6R) release after incubating both
unstimulated (h) and stimulated (j) peripheral blood mononuclear
cells (PBMCs) for 24 hours. The results are obtained from the same
four groups of Figure 1 and are expressed as mean 6 SEM. *P , 0.01
vs. unstimulated control, UR, and PMMA; **P , 0.01 vs. corresponding
unstimulated value; 8P , 0.01 vs. stimulated control, UR, and PMMA.
Fig. 3. Linear regression analysis between unstimulated (x axis,
sIL-6R basal) and lipopolysaccharide (LPS)-stimulated (y axis, sIL-6R
LPS) sIL-6R release by PBMC. The analysis includes all subjects of
the same four groups of two previous figures: control (j), UR (r), CU
(d), and PMMA (m). sIL-6R release values under LPS result highlyproduction in controls (267.5 6 26.5 pg/mL), UR (258.4 6
correlated with the values obtained in basal condition (r 5 0.967, P ,38.1 pg/mL) and PMMA (288.4 6 24.6 pg/mL). When 0.001).
stimulated by LPS, PBMC released a significantly (P ,
0.01) greater amount of sIL-6R in all groups: controls,
349.0 6 30.2 (33.6% as compared with unstimulated
Table 1. Interleukin-6 (IL-6) production (pg/mL) after incubatingPBMC release); UR, 312.8 6 45.9 (21%); CU, 1049.0 6
both unstimulated (Basal) and stimulated PBMC for 24 hours
100.6 (19%); and PMMA, 348.3 6 35.0 (21%) pg/mL
Control UR CU PMMA(Fig. 2). sIL-6R release by stimulated PBMCs resulted
Basal 56.767.2 120.1635.5 375.5626.1a 64.269.4significantly (P , 0.01) higher in patients dialyzed with
Stimulated 289.2616.5c 234.9619.1c 363.0620.5b 257.464.6ccuprophan membranes as compared with the other stim-
Results were obtained from the four groups: control, uremic nondialyzedulated three groups (Fig. 2). (UR), uremic dialyzed with cuprophan membranes (CU) and uremic dialyzed
with polymethylmethacrylate membranes (PMMA). Data are expressed asNo statistically significant difference was obtained
mean 6 SEM.among the four groups in the absolute value of increase aP , 0.01 vs. Basal control, UR and PMMA
bP , 0.01 vs. Stimulated control, UR, PMMAin sIL-6R release observed by stimulated PBMCs as com-
cP , 0.01 vs. Basalpared with basal values (81.5 6 17.5, 54.4 6 7.8, 167.2 6
55.0, and 59.9 6 14.1 pg/mL in controls, UR, CU, and
PMMA, respectively).
Soluble IL-6 receptor release values found under mito- 0.9, 1.2 6 0.6, and 1.7 6 0.7 pg/mL in controls, UR, and
genic stimulation were highly and positively correlated PMMA, respectively).
with the values obtained without stimulation (r 5 0.967,
Basal and stimulated PBMC release of IL-6P , 0.001; Fig. 3). Figure 3 also shows that uremic pa-
tients dialyzed with CU exhibit the highest values in both As reported in Table 1, uremic patients dialyzed with
unstimulated and stimulated condition; no difference is cuprophan membranes showed a significantly (P , 0.01)
seen among the other three groups (controls, UR, and higher value of IL-6 production by unstimulated PBMCs
PMMA). as compared with values obtained in controls, UR, and
PMMA. No difference was observed in basal IL-6 release
sIL-6R urinary excretion among controls, UR, and PMMA groups. When the
Urinary excretion of sIL-6R in uremic nondialyzed PBMC production of IL-6 was stimulated by LPS, PBMC
patients was significantly (P , 0.001) lower (0.44 6 0.1 harvested from uremic patients dialyzed with the cupro-
ng/min) as compared with values obtained in control phan membranes released a significantly (P , 0.01)
healthy subjects (2.3 6 0.3 ng/min). higher amount of IL-6 than PBMCs isolated from con-
trols, UR, and PMMA. No difference, however, was
Plasma levels of IL-6 observed between unstimulated and stimulated IL-6 pro-
Uremic patients dialyzed with CU had plasma levels duction in CU patients. In contrast, the other groups
(controls, UR, and PMMA) showed a statistically sig-of IL-6 that were significantly (P , 0.05) higher (5.4 6
1.3 pg/mL) than those observed in all other groups (1.8 6 nificant (P , 0.01) difference (increase under stimula-
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1). The results also demonstrated a spontaneous sIL-6R
release by PBMCs harvested from uremic patients dia-
lyzed with cuprophan membranes that was significantly
greater than that of uremic nondialyzed patients and
patients regularly dialyzed with a more biocompat-
ible, less activating complement, dialysis membrane
(PMMA). The latter two groups exhibited release values
similar to those of normal healthy subjects (Fig. 2). These
results suggest PBMC activation, presumably secondary
to the poor biocompatibility of the dialysis cuprophan
membranes. Such a state of activation could be responsi-
ble for the shedding, or de novo synthesis, of the sIL-6R.
LPS stimulation, in fact, induced a PBMC activation,
with a statistically significant increase in sIL-6R release
in all groups (Fig. 2). sIL-6R production under mitogen
stimulation was highly and positively correlated with
basal values, suggesting an almost similar quantitative
response to the mitogenic stimulus in all groups, indepen-
dently from their basal activation status (Fig. 3).
As mentioned, the circulating levels of sIL-6R were
significantly higher in nondialyzed uremic patients than
those of control subjects and were similar to uremic
patients dialyzed with cuprophan membranes. Since
sIL-6R release by PBMCs was not different in nondia-
lyzed uremic patients and control subjects, the increased
plasma levels of sIL-6R in the former group do not neces-
sarily reflect an increased receptor release, secondary to
inflammatory states and monocyte activation, but pre-
sumably are due to the reduced renal excretion of these
soluble receptors. Our data on urinary excretion of
sIL-6R confirm this hypothesis, demonstrating an almost
fivefold reduction in urinary excretion of these receptors
Fig. 4. Linear regression analysis between IL-6 (x axis) and sIL-6R (y in nondialyzed uremic patients as compared with healthyaxis) release by PBMCs in both unstimulated (basal, A) and stimulated
subjects.(LPS, B) conditions. Symbols are: control (j), UR (r), CU (d), and
PMMA (m). sIL-6R release values are highly correlated with IL-6- The uremic patients dialyzed with PMMA membranes
values in both the unstimulated (r 5 0.735, P , 0.001) and stimulated showed low circulating plasma levels of sIL-6R despite(r 5 0.521, P , 0.001) conditions.
the fact that their renal function was almost absent. This
finding could be explained by either the absence of
monocyte activation or the adsorption of this soluble
receptor by the hydrophobic PMMA membrane. Fuji-tion) between the unstimulated and the stimulated con-
mori, Naito, and Miyazaki have recently demonstrateddition.
a significant adsorption of complement fragments andInterleukin-6 release by PBMCs was statistically corre-
cytokines (IL-1, IL-6, and TNF) by different hydropho-lated to the sIL-6R PBMC release in both basal (r 5
bic dialysis membranes, particularly by polyacrylonitrile0.735, P , 0.001) and stimulated (r 5 0.521, P , 0.001)
and PMMA [24]. A similar phenomenon could also beconditions (Fig. 4). IL-6 production in basal condition
hypothesized for sIL-6R.was also statistically correlated with IL-6 release under
Regarding IL-6 plasma levels and PBMC release, ourstimulation (r 5 0.710, P , 0.001).
results are in agreement with previous studies [11, 12,
25] and demonstrate, in patients dialyzed with cuprophan
DISCUSSION membrane, a production of IL-6 by stimulated PBMCs
The results of this study clearly demonstrate that uremic not different from that obtained in an unstimulated con-
patients dialyzed with cuprophan membranes showed dition (Table 1). These data confirm a reduction in the
circulating levels of sIL-6R that were significantly higher ability of PBMCs, when challenged with mitogen, to
(almost 60%) than healthy control subjects but similar release adequate amounts of this proinflammatory cyto-
kine in patients dialyzed with cuprophan membranesto those observed in uremic nondialyzed patients (Fig.
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[12]. A down-regulation of recurrently activated lympho- could play a crucial role in increasing the production of
acute-phase protein by human hepatocytes [33].mononuclear cells to synthesize and release cytokines,
The possible clinical implications of our findings areas proposed by Zaoui and Hakim [26], probably explains
that elevated levels of sIL-6R may promote or increasethis phenomenon. Chronic use of a more biocompatible,
the response to IL-6 and therefore enhance its inflam-less complement-activating membrane (such as PMMA)
matory effects.may reverse this alteration. IL-6 release resulted statisti-
Interleukin-6 is the major regulator of the hepaticcally correlated to sIL-6R release, in both basal and
acute phase protein response during inflammation withstimulated conditions (Fig. 4), suggesting a role of the
changes in circulating protein levels and increase in syn-same cytokine on sIL-6R release.
thesis (up to 1000-fold or more) of the two major acute-Naturally occurring sIL-6R was first detected as an IL-
phase proteins, C-reactive protein (CRP) and serum am-6–binding protein present in the urine of normal subjects
yloid A (SAA) [34–37]. It is now well known that IL-6[17]. The purification of this IL-6–binding molecule has
is the major cytokine inducing transcription of humanfurther confirmed its identity with the extracellular por-
CRP during the acute phase-response [38, 39]. Surpris-tion of the membrane receptor gp 80 (IL-6R). IL-6, in
ingly, it should be noted that CRP in turn causes a three-the circulation, is bound to the sIL-6R, and there is a
fold increase of sIL-6R production [40].large depot of sIL-6R molecules that might further bind
In a previous study, we demonstrated that the in-IL-6 synthesized, after stimulation, by monocytes, fibro-
creased PBMC production of IL-6 was paralleled, inblasts, or endothelial cells [15]. Soluble IL-6R is gener-
uremic patients dialyzed with cuprophan membrane, byated independently by either one of these two mecha-
a striking increment of the plasma levels of SAA [12].nisms: a shedding from the membrane-bound receptor
Accordingly, a strong linear correlation was detectedprotein (particularly under mitogenic stimulation) or, in
between IL-6 PBMC production and SAA plasma levels,the basal condition, an alternative splicing of mRNA
indicating that IL-6 may be involved in the increase ofleading to the loss of the transmembrane domain [27].
SAA levels in patients dialyzed with cuprophan mem-In contrast to soluble receptors of other cytokines,
branes [12]. Similar considerations have been proposedsuch as IL-1, IL-2, and TNF [28–30], which are known
for CRP by Panichi et al [41].to competitively inhibit the functions of their ligands,
C-reactive protein and SAA levels have shown prog-sIL-6R is able to bind IL-6 with affinity comparable to
nostic value in predicting cardiovascular events [42].that of the membrane-associated receptor (IL-6R or gp
Bergstro¨m et al first suggested that CRP may predict80), thereby enhancing the actions of IL-6 [15]. The com-
mortality in hemodialysis patients (abstract; J Am Socplex IL-6/sIL-6R may associate on cell surface with two
Nephrol 6:573, 1995). Kaysen, Stevenson, and Depner
molecules of the transmembrane signal-transducing re-
recently found that serum albumin concentration [43], a
ceptor component gp 130 to mediate the IL-6 signal. powerful predictor of death in end-stage renal disease
sIL-6R potentiates the IL-6 actions on cells already patients [44], was also significantly and negatively corre-
responsive to IL-6, that is, on cells expressing either gp80 lated with both CRP and SAA. In addition to being
or gp 130 on their surface. More important, sIL-6R regulated by dietary protein intake, in fact, albumin is
bound to IL-6 elicits an IL-6–specific signal on cells that a negative acute-phase reactive protein, as its synthesis
expresses gp 130 but not the gp 80 (IL-6R) protein on is actively suppressed as part of the response to inflam-
their surface and, therefore, are not able to bind IL-6. mation [45].
This implies that cells releasing sIL-6R protein render Zimmermann et al have recently evaluated whether an
other cells responsive to IL-6 (trans-signaling) [15]. The activated acute-phase response may influence or predict
soluble form of gp 130 (molecular weight, 90 to 110 cardiovascular risk in uremic dialyzed patients [46]. The
kD) has no detectable binding affinity for IL-6. The authors found that a considerable number of hemodialy-
association between the complex IL-6/sIL-6R and the sis patients exhibit an activated acute-phase response,
soluble gp 130 has been detected in the serum of patients which is closely related to high levels of atherogenic
and could be demonstrated to have an antagonistic activ- vascular risk factors and cardiovascular death [46]. Fur-
ity, negatively regulating the IL-6 signal [31]. ther studies are necessary to better clarify the role of
A major role of the sIL-6R in potentiating the IL-6 IL-6 and of its soluble circulating receptor in eliciting
effects has been shown by Gaillard et al [32]. These the inflammatory response and the CRP synthesis in
authors, using a new culture system in which the superna- uremic dialyzed patients.
tant recirculated permanently through an anti-sIL-6R In conclusion, our results demonstrate more elevated
affinity column removing all sIL-6R from the culture levels of circulating sIL-6R in patients dialyzed with cu-
medium, demonstrated that sIL-6R sustained the prolif- prophan membranes. These elevated levels, caused by
eration of multiple myeloma cells that need IL-6 to pro- the agonistic role of the soluble receptor, could amplify
the inflammatory deleterious effects of IL-6 and signifi-liferate [32]. It is still matter of debate whether sIL-6R
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